On 14 June 2018 in Geneva, Switzerland, The Stop TB Partnership’s Global Drug Facility (GDF) announced agreements signed with 28 medicines manufacturers for 83 products that will substantially reduce the prices of medicines used in the treatment of tuberculosis (TB). As an outcome of GDF ’s recent competitive tender, savings of approximately USD 31 million are expected in the April 2018 to March 2019 period.
The USD 31 million in savings represent 14% of USD 217 million in TB medicines delivered by GDF in 2017. If the USD 31 million in savings were used to purchase additional medicines, the savings would be sufficient to provide 960,000 people with drug-sensitive TB medicines, 53,000 people with shorter regimens for drug-resistant TB, or up to 37,000 people with conventional regimens for drug-resistant TB.
Reduced medicine prices translate into lower TB treatment costs. GDF’s new prices for conventional, multidrug-resistant (MDR) TB treatment regimens are now as low as USD 812, leading to savings of up to 33% compared to 2017 prices of USD 1,214. Similar price reductions were realized for shorter MDR-TB treatment regimens which are now as low as USD 571, resulting in 27% savings from the 2017 price of USD 779.
To read the full publication, click here.
Source: http://www.stoptb.org
